It was only yesterday that BlackRock CEO Larry Fink said that “we’re probably in a recession” right now. Most investors ...

Bank of America Securities analyst Tim Anderson reiterated a Buy rating on Metsera, Inc. (MTSR – Research Report) today and set a price target ...

Despite several big deals that buoyed the numbers, North America early- and seed-stage investment declined to multiquarter ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for Metsera in a report issued on Thursday, March 27th. Cantor Fitzgerald analyst P. Agrawal now ...

Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...

After an IPO this year, Metsera is making its best effort to catch up to obesity drug giants Eli Lilly and Novo Nordisk.

"2024 was a year of exceptional execution and acceleration at Metsera," said Whit Bernard, Chief Executive Officer of Metsera. "We advanced MET-097i, our monthly, fully-biased GLP-1 RA injectable ...

With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply of the upcoming oral options will be the sector’s next great challenge.

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs ...

Trident's strategic collaboration with e-commerce players Silkoo and Haitu will combine their unique strengths to drive innovation and mutual growth ...